Introducing our hiEX™ Research iPSC Exosomes For powering next-generation regenerative medicine research June 24, 2025 11:00 AM PST Meet our hiEX™ Research iPSC Exosomes, a new research-use-only product designed to enable scientists to explore the therapeutic potential of iPSC-derived exosomes in areas such as wound healing, aging, and nerve regeneration Isolated from a single, well-characterized induced […]
Our two new hypoimmunogenic hiPSC products are here to accelerate your allogeneic therapies May 20, 2025 8:30 AM PST We are thrilled to announce the launch of our first hypoimmunogenic hiPSC products, which are designed to empower researchers developing next-generation allogeneic therapies. The ActiCells™ RUO Hypo hiPSCs (Cat.# ASE-9550) and the ActiCells™ RUO TARGATT™ Hypo […]
Announcing our Drug Master File Submission to the US FDA for our GMP-Grade iPSC Cell Line April 14, 2025 12:00 PM PST We are thrilled to announce that we have submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for our ActiCells™ GMP Human Induced Pluripotent Stem Cell […]
Applied StemCell’s Brand Refresh: Building the biology-based future January 30, 2025 12:00 PM PST Drug discovery is a famously challenging endeavor, with a 96% failure rate, a $1B+ price tag to develop a single drug, and a 10+ year timeline from discovery to commercialization. What if we could invert those numbers? Turn a 96% failure […]
January 14, 2025 9:00 AM PST Milpitas, California, January 2025 – Applied StemCell, Inc., a proven CRO/CDMO and gene editing technology developer, is pleased to welcome Todd Garland to our Board of Directors and Mike Yurkovich as Vice President of Sales. Todd Garland brings over 30 years of expertise in product management, sales, and commercial […]
October 01, 2024 10:00 AM PST MILPITAS, Calif. – Applied StemCell, Inc. is proud to announce the successful approval of its latest U.S. patent which covers HLA-F engineered universal donor cells, marking a significant advancement in cell transplantation therapy and the first step towards an allogeneic cell therapy development platform. This innovation not only […]
